Format

Send to

Choose Destination
Endocrinol Metab (Seoul). 2019 May 9. [Epub ahead of print]

The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes.

Author information

1
Department of Internal Medicine, Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.
2
Cardiovascular and Metabolic Disease Center (CMDC), Inje University, Busan, Korea.
3
Department of Neurology, Inje University Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.
4
Cardiovascular and Metabolic Disease Center (CMDC), Inje University, Busan, Korea. drwonjc@gmail.com.

Abstract

The prevalence of type 2 diabetes mellitus (T2DM), which is associated with cardiovascular morbidity and mortality, is increasing worldwide. Although there have been advances in diabetes treatments that reduce microvascular complications (nephropathy, neuropathy, retinopathy), many clinical studies have found that conventional oral hypoglycemic agents and glucose control alone failed to reduce cardiovascular disease. Thus, incretin-based therapies including glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2Is) represent a new area of research, and may serve as novel therapeutics for treating hyperglycemia and modifying other cardiovascular risk factors. Recently, it has been confirmed that several drugs in these classes, including canagliflozin, empagliflozin, semaglutide, and liraglutide, are safe and possess cardioprotective effects. We review the most recent cardiovascular outcome trials on GLP-1RAs and SGLT-2Is, and discuss their implications for treating patients with T2DM in terms of protective effects against cardiovascular disease.

KEYWORDS:

Diabetes mellitus; Heart failure; Hypoglycemic agents; Myocardial ischemia

PMID:
31099200
Free full text

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Supplemental Content

Full text links

Icon for Korean Endocrine Society
Loading ...
Support Center